Search results for "uno"

showing 10 items of 14944 documents

Treatment strategies for lysosomal storage disorders.

2017

Over the past several years the number of treatments available for patients with lysosomal storage disorders has rapidly increased. Haematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction, and chaperone therapies are currently available, and gene therapies and other treatments are rapidly advancing. Despite remarkable advances, the efficacy of most of these therapies is limited, particularly because the treatments are usually initiated when organ damage has already occurred. To circumvent this limitation, screening in newborn infants for lysosomal storage disorders has been introduced in many countries. However, this screening is complicated by the broad cl…

0301 basic medicineGenetic enhancementLysosomal storage disordersBioinformatics03 medical and health sciences0302 clinical medicineDevelopmental NeuroscienceSlow progressionMedicineHumansEnzyme Replacement Therapybusiness.industryHematopoietic Stem Cell TransplantationEnzyme replacement therapyGenetic TherapyOrgan damageTransplantationLysosomal Storage Diseases030104 developmental biologyPediatrics Perinatology and Child HealthImmunologyTreatment strategyNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryMolecular ChaperonesDevelopmental medicine and child neurology
researchProduct

Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape.

2019

Abstract Foxp3+ regulatory T cells (Tregs) sustain immune homeostasis and may contribute to immune escape in malignant disease. As a prerequisite for developing immunologic approaches in cancer therapy, it is necessary to understand the ontogeny and the antigenic specificities of tumor-infiltrating Tregs. We addressed this question by using a λ-MYC transgenic mouse model of endogenously arising B-cell lymphoma, which mirrors key features of human Burkitt lymphoma. We show that Foxp3+ Tregs suppress antitumor responses in endogenous lymphoma. Ablation of Foxp3+ Tregs significantly delayed tumor development. The ratio of Treg to effector T cells was elevated in growing tumors, which could be …

0301 basic medicineGenetically modified mouseCancer ResearchLymphoma B-CellImmunologychemical and pharmacologic phenomenaMice TransgenicT-Lymphocytes RegulatoryEpitope03 medical and health sciences0302 clinical medicineAntigenCell Line TumorMHC class ImedicineAnimalsAntigensbiologyEffectorFOXP3hemic and immune systemsmedicine.diseaseLymphomaMice Inbred C57BL030104 developmental biologyTumor Escape030220 oncology & carcinogenesisCancer researchbiology.proteinTumor EscapePeptidesCancer immunology research
researchProduct

IL-17A mediated endothelial breach promotes metastasis formation

2015

Abstract The role of the IL23/IL17A axis in tumor–immune interactions is a matter of controversy. Although some suggest that IL17A-producing T cells (TH17) can suppress tumor growth, others report that IL17A and IL23 accelerate tumor growth. Here, we systematically assessed the impact of IL17A-secreting lymphocytes in several murine models of tumor lung metastasis. Genetic fate mapping revealed that IL17A was secreted within lung metastases predominantly by γδ T cells, whereas TH17 cells were virtually absent. Using different tumor models, we found Il17a−/− mice to consistently develop fewer pulmonary tumor colonies. IL17A specifically increased blood vessel permeability and the expression …

0301 basic medicineGenetically modified mouseCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsEndotheliumImmunologyMelanoma ExperimentalVascular permeability610 Medicine & healthBiology10263 Institute of Experimental ImmunologyCapillary Permeability03 medical and health sciencesCarcinoma Lewis LungCell Line TumormedicineCell AdhesionAnimals1306 Cancer ResearchCell adhesionMice Knockout2403 ImmunologyLungMelanomaInterleukin-17Transendothelial and Transepithelial MigrationEndothelial Cellsmedicine.diseaseMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureCell culture570 Life sciences; biologyInterleukin 17Endothelium VascularNeoplasm Transplantation
researchProduct

Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer's disease during lifespan.

2017

Alzheimer's disease (AD) is the most common form of dementia and one of the major causes of disability and dependency in older people. Accumulating evidences link gut microbiota with different diseases and its relationship with neurodegenerative diseases is becoming most intriguing. This study was aimed to compare the gut microbiota of transgenic APP/PS1 (TG) mice, a well‐established deterministic mouse model of AD, with their C57BL/6 wild‐type (WT) littermates. Faecal samples were collected from 3‐, 6‐ and 24‐month‐old mice and analysed by pyrosequencing of the V1–V3 region of the bacterial 16S rRNA genes. Bacterial profiles were similar in all young mice (3 months old), and started to div…

0301 basic medicineGenetically modified mouseMaleAgingRikenellaceaeTransgeneFirmicutesMice TransgenicDiseaseGut floraApplied Microbiology and Biotechnology03 medical and health sciencesMiceAlzheimer DiseaseRNA Ribosomal 16SProteobacteriamedicineDementiaIndicatorsAnimalsHumansNeuroinflammationMarkersbiologyIntestinal microbiologyBacteroidetesbiology.organism_classificationmedicine.diseaseGastrointestinal MicrobiomeMice Inbred C57BLDisease Models Animal030104 developmental biologyAgeingImmunologyMicrobial structureDisease processesLetters in applied microbiology
researchProduct

Cytoskeletal transgelin 2 contributes to gender-dependent adipose tissue expandability and immune function

2019

During adipogenesis, preadipocytes' cytoskeleton reorganizes in parallel with lipid accumulation. Failure to do so may impact the ability of adipose tissue (AT) to shift between lipid storage and mobilization. Here, we identify cytoskeletal transgelin 2 (TAGLN2) as a protein expressed in AT and associated with obesity and inflammation, being normalized upon weight loss. TAGLN2 was primarily found in the adipose stromovascular cell fraction, but inflammation, TGF-β, and estradiol also prompted increased expression in human adipocytes. Tagln2 knockdown revealed a key functional role, being required for proliferation and differentiation of fat cells, whereas transgenic mice overexpressing Tagl…

0301 basic medicineGenetically modified mouseMalemedicine.medical_specialtyTHP-1 CellsBlotting WesternAdipose tissueMuscle ProteinsInflammationMice TransgenicDiet High-FatBiochemistry03 medical and health sciencesMice0302 clinical medicineImmune systemSex FactorsInternal medicineGeneticsmedicineAdipocytesAnimalsHumansObesityadipocyte protein 2CytoskeletonMolecular BiologyCytoskeletonInflammationbiologyMicrofilament ProteinsPhenotypeImmunohistochemistryMice Inbred C57BL030104 developmental biologyEndocrinologyAdipose TissueAdipogenesisbiology.proteinFemalemedicine.symptom030217 neurology & neurosurgeryBiotechnology
researchProduct

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

2021

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.

0301 basic medicineGenetically modified mouseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TransgenevirusesImmunologyefficacylcsh:Medicineimmunogenicitychallenge study03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicinePharmacologyMessenger RNAbiologybusiness.industrySARS-CoV-2Brief ReportImmunogenicitylcsh:RCOVID-19VirologyTiter030104 developmental biologyInfectious DiseasesmRNA vaccineImmunizationbiology.proteinAntibodybusinessVaccines
researchProduct

Gradual development of psoriatic skin lesions by constitutive low-level expression of IL-17A

2016

Psoriasis is a common chronic inflammatory skin disease restricted to humans. The understanding of its pathogenesis has long been hampered by the lack of suitable chronic mouse models. The cytokine IL-17A has emerged as a key player in epithelial immune responses and the defense against extracellular pathogens. Moreover, enhanced expression of IL-17A can turn pathologic and is closely associated with psoriasis. In this study, we generated a novel transgenic mouse model that recapitulates many characteristics of psoriasis. DC-1L-17A(ind) mice with constitutive low-level expression of IL-17A by CD11c(+) cells gradually develop skin lesions during adult life. The lesions preferentially occur a…

0301 basic medicineGenetically modified mousemedicine.medical_treatmentImmunologyCD11cInflammationAnimals Genetically ModifiedPathogenesisMice03 medical and health sciences0302 clinical medicineImmune systemSDG 3 - Good Health and Well-beingPsoriasismedicineAnimalsHumansPsoriasisCells CulturedSkinbusiness.industryInterleukin-17Dendritic Cellsmedicine.diseaseCD11c AntigenDisease Models Animal030104 developmental biologyCytokineImmunologyCytokinesInterleukin 17medicine.symptombusiness030215 immunologyCellular Immunology
researchProduct

Production Conditions Affect the In Vitro Anti-Tumoral Effects of a High Concentration Multi-Strain Probiotic Preparation.

2016

A careful selection of the probiotic agent, standardization of the dose and detailed characterization of the beneficial effects are essential when considering use of a probiotic for the dietary management of serious diseases. However, changes in the manufacturing processes, equipment or facilities can result in differences in the product itself due to the live nature of probiotics. The need to reconfirm safety and/or efficacy for any probiotic product made at a different factory is therefore mandatory. Recently, under the brand VSL#3®, a formulation produced by a manufacturer different from the previous one, has been commercialized in some European countries (the UK and Holland). VSL#3 is a…

0301 basic medicineGenetics and Molecular Biology (all)Cell LinesCancer Treatmentlcsh:MedicineApoptosisMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Biochemistrylaw.inventionProbiotic0302 clinical medicinelawMedicine and Health SciencesMedicineCell Cycle and Cell DivisionEnzyme-Linked Immunoassayslcsh:ScienceStainingMultidisciplinaryCell DeathMedicine (all)Inflammatory Bowel DiseasesCell StainingApoptotic deathProbiotic agentOncologyCell Processes030211 gastroenterology & hepatologyBiological CulturesResearch ArticleTumor cellsAffect (psychology)Research and Analysis MethodsMicrobiology03 medical and health sciencesImmunoassaysBeneficial effectsBacteriabusiness.industryProbioticslcsh:ROrganismsBiology and Life SciencesCell BiologyIn vitroBiotechnology030104 developmental biologyAgricultural and Biological Sciences (all)Specimen Preparation and TreatmentImmunologyImmunologic Techniqueslcsh:QCaco-2 CellsbusinessPLoS ONE
researchProduct

Ectopic expression of CXCL13, BAFF, APRIL and LT-ß is associated with artery tertiary lymphoid organs in giant cell arteritis

2016

ObjectivesTo investigate whether artery tertiary lymphoid organs (ATLOs) are present in giant cell arteritis (GCA) and that their formation is associated with the ectopic expression of constitutive lymphoid tissue-homing chemokines.MethodsReverse transcriptase PCR, immunohistochemical and immunofluorescence analysis were used to determine the presence of ectopic ATLOs in GCA and the expression of chemokines/chemokine receptors and cytokines involved in lymphoneogenesis in the temporal artery samples obtained from 50 patients with GCA and 30 controls. The presence of lymphatic conduits, of follicular dendritic cells (FDCs) precursors and lymphoid tissue inducer cells was also investigated. F…

0301 basic medicineGenetics and Molecular Biology (all)ChemokineChemokines; Cytokines; Giant Cell Arteritis; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all); Immunology and AllergyHigh endothelial venulesImmunologyBiologyBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesChemokine receptor0302 clinical medicineRheumatologyChemokines; Cytokines; Giant Cell ArteritisImmunology and AllergyCXCL13B-cell activating factorCytokineGiant Cell Arteriti030203 arthritis & rheumatologyBiochemistry Genetics and Molecular Biology (all)Follicular dendritic cellsSettore MED/16 - Reumatologia030104 developmental biologyLymphatic systemChemokineImmunologybiology.proteinEctopic expression
researchProduct

Clinical efficacy of α4 integrin block with natalizumab in ankylosing spondylitis

2016

We describe the impact of α4-β1/7 blockade with natalizumab, a recombinant humanised immunoglobulin (Ig) G4κ monoclonal antibody (mAb) targeted to the α4 subunit of the α4β1 and α4β7 integrins, on the gut and spine inflammation in a patient with ankylosing spondylitis (AS) who developed multiple sclerosis after treatment with tumour necrosis factor (TNF)-blocking agents. A 45-year-old man with human leucocyte antigen (HLA)-B27-positive AS was admitted in January 2007. He had been diagnosed with AS 4 years earlier based on the presence of inflammatory back pain, peripheral arthritis, radiographic bilateral grade 2 sacroiliitis, HLA-B27 positivity. At that time, he had evidence of chronic int…

0301 basic medicineGenetics and Molecular Biology (all)medicine.drug_classImmunologyHuman leukocyte antigenMonoclonal antibodyBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineNatalizumabRheumatologymedicineAdalimumabImmunology and Allergy030203 arthritis & rheumatologyInflammationAnkylosing spondylitisBiochemistry Genetics and Molecular Biology (all)business.industryMultiple sclerosisMedicine (all)Sacroiliitismedicine.diseaseTreatmentSettore MED/16 - Reumatologia030104 developmental biologyImmunologyTumor necrosis factor alphaSpondyloarthritibusinessmedicine.drug
researchProduct